Trial Profile
A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 24 Dec 2020 Status changed from recruiting to completed.
- 08 Jul 2020 Planned End Date changed from 1 Apr 2020 to 20 Nov 2020.
- 08 Jul 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Nov 2020.